SCHEMBL2774364

SCHEMBL2774364

N#Cc1cccc(/C=C/c2cccc(C#N)c2)c1

nearest known ligand 0.65

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 3/20 0.65
P4HB P07237 9/20 0.56
GRIN2D O15399 2/20 0.53
GRIN3B O60391 2/20 0.53
GRIN1 Q05586 2/20 0.53
GRIN2A Q12879 2/20 0.53
GRIN2B Q13224 2/20 0.53
GRIN2C Q14957 2/20 0.53
GRIN3A Q8TCU5 2/20 0.53
MAOA P21397 2/20 0.49
MAOB P27338 2/20 0.49
ENPP2 Q13822 1/20 0.47
RAF1 P04049 1/20 0.46
TSHR P16473 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1687910 1.00 FBP1 (0.65) FBP1P4HBGRIN2DGRIN3BGRIN1
SCHEMBL9186668 0.96 FBP1 (0.61) FBP1P4HBGRIN2DGRIN3BGRIN1
SCHEMBL21574844 0.96 FBP1 (0.61) FBP1P4HBGRIN2DGRIN3BGRIN1
SCHEMBL9186663 0.96 FBP1 (0.61) FBP1P4HBGRIN2DGRIN3BGRIN1
SCHEMBL10661672 0.94 FBP1 (0.59) FBP1P4HBGRIN2DGRIN3BGRIN1
SCHEMBL1405482 0.94 FBP1 (0.59) FBP1P4HBGRIN2DGRIN3BGRIN1
SCHEMBL1405480 0.94 FBP1 (0.59) FBP1P4HBGRIN2DGRIN3BGRIN1
SCHEMBL30630950 0.94 FBP1 (0.59) FBP1P4HBGRIN2DGRIN3BGRIN1
SCHEMBL21574806 0.92 FBP1 (0.57) FBP1P4HBGRIN2DGRIN3BGRIN1
SCHEMBL9190221 0.92 FBP1 (0.57) FBP1P4HBGRIN2DGRIN3BGRIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100302927-A1 OPTICAL DATA STORAGE MEDIUM AND METHODS FOR USING THE SAME GENERAL ELECTRIC COMPANY (US) 2010-12-02 US disclosed
US-7553809-B2 Fc receptor modulators and uses thereof ILEXUS PTY LIMITED (AU) 2009-06-30 US disclosed
US-20060057144-A1 Fc receptor modulators and uses thereof ILEXUS PTY LIMITED (AU) 2006-03-16 US disclosed
US-6835753-B2 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt ILEXUS PTY LIMITED (AU) 2004-12-28 US disclosed
US-20020061844-A1 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt ILEXUS PTY LIMITED 2002-05-23 US disclosed
US-6355683-B1 ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE ILEXUS PTY LIMITED (AU) 2002-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020061844-A1 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt FCGR2A, FCGR1A, FCER2 FBP1 3131/4885P4HB 2556/4885GRIN2D 1554/4885
US-20060057144-A1 Fc receptor modulators and uses thereof FCGR1A, FCER2, FCGR2A FBP1 1527/4885P4HB 2723/4885GRIN2D 1920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.